Últimas noticias sobre Mangoceuticals (NASDAQ:MGRX) Bolsa

Mangoceuticals

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Mangoceuticals Inc

Truist Securities analyst Joel Fishbein reiterates Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Buy and raises the price target from $220 to $250.

News

Price Target

Reiteration

Analyst Ratings

CHKP

Truist Securities Reiterates Buy on Check Point Software, Raises Price Target to $250

WIIM

POET

POET Technologies shares are trading higher after the company announced it signed an agreement to develop a novel optical enginefor the use in high-frequency securities trading for firms in the global capital markets.

Keybanc analyst Eric Gonzalez maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Overweight and raises the price target from $600 to $630.

Keybanc Maintains Overweight on Mastercard, Raises Price Target to $630

Truist Securities analyst Michael Roxland reiterates Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) with a Buy and lowers the price target from $245 to $215.

Truist Securities Reiterates Buy on Avery Dennison, Lowers Price Target to $215

On Thursday, Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) Canada announced a substantial investment plan, committing C$6.5 billion ($3.88 billion) to its <a target="_blank" href="https://www.walmartcanada.ca/news/2025/01/30/walmart-canada-announces-landmark--6-5-billion-investment-in-its" rel="noreferrer noopener">operations over the next five years.</a>
The objective is to broaden its presence and improve service offerings throughout Canada. The funding will facilitate the development of new Supercentres, upgraded distribution centers, and technological advancements designed to enhance the customer shopping experience and optimize Walmart's operations in the country.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43337656/levi-strauss-sees-gloomy-fy25-despite-solid-q4-stocks-plunge" rel="noreferrer noopener">Levi Strauss Sees Gloomy FY25 Despite Solid Q4</a>
The C$6.5 billion investment plan includes the launch of five new Supercentres by 2027. Walmart will begin by establishing locations in Ontario and Alberta, with prominent stores in Mississauga and Oakville.
The Port Credit Supercentre is set to open in the summer of 2025, strategically positioned to serve high-traffic areas.
"This $6.5 billion investment is the largest we've made in Canada towards expanding our footprint since we first arrived here 30 years ago," said regional CEO Walmart Canada, Chile, Mexico and Central America, Gui Loureiro.
Another Oakville store, opening toward the end of 2025, will offer a comprehensive selection of items, such as fresh produce, meats, dairy products, and pharmacy services.
In addition to opening new stores, Walmart Canada is also planning to improve its supply chain. The company is set to launch its distribution center in Vaughan by spring 2025, boosting distribution efficiency and optimizing operations nationwide.
The retailer has entered into an agreement with fleet services provider Canada Cartage to buy Walmart Canada's fleet business. The development follows the completion of Walmart Canada's previous C$3.5 billion investment, which started in 2020 and involved the modernization of more than 180 stores.
Key upgrades included turning the Mississauga-Square One Supercentre into a flagship location. The ongoing expansion is expected to help maintain Walmart's competitive edge in the Canadian retail sector.
In 2024, Walmart Canada allocated almost $200 million for pay raises for frontline employees.
On the other hand, last week, Amazon.com&nbsp;Inc. <a target="_blank" href="https://www.benzinga.com/topic/amazon" rel="noreferrer noopener">announced that it</a> was withdrawing its operations in Quebec, Canada, and losing about 1,700 full-time jobs.
The American e-commerce giant's move followed U.S. President Donald Trump's threat to slap <a target="_blank" href="https://www.benzinga.com/25/01/43101141/chinese-stocks-rally-after-trump-skips-tariff-threats-boosting-market-optimism" rel="noreferrer noopener">25% tariffs on</a> imports from Canada and Mexico on February 1.
Amazon has seven sites in Quebec, including sorting centers and warehouses, most of which are in the Montreal area.
Price Action: WMT shares are trading higher by 0.40% at $98.26 at the last check on Friday.
Read Next: <a href="https://www.benzinga.com/25/01/43330033/molson-coors-partners-with-fever-tree-to-expand-non-alcoholic-portfolio" target="_blank" rel="noreferrer noopener">Molson Coors Takes 8.5% Ownership Stake In Fever-Tree To Stir Up US Mixer Game: Details</a>
Image via Shutterstock

General

Walmart Canada To Invest About $3.8 Billion Over Five Years

Shares of Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) came under pressure in early trading on Friday, despite the company reporting <a href="https://www.benzinga.com/news/earnings/25/01/43345282/mastercard-q4-earnings-revenue-and-eps-beat-strong-growth-in-payments-and-cross-border-transactions">upbeat fourth-quarter results</a>.
The companyreported its quarterly results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<ul>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e53e894ece4e600011fe266/will-nance">analyst Will Nance</a> reiterated a Buy rating, while lifting the price target from $572 to $628.</li>
<li>KeyBanc <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6454c3bfaaeafc00016ab1c3/alex-markgraff">analyst Alex Markgraff</a> maintained an Overweight rating, while raising the price target from $600 to $630.</li>
<li>RBC Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880b6f377f9dd00011b0ab2/matthew-hedberg">analyst Daniel Perlin</a> reaffirmed an Outperform rating, while raising the price target from $572 to $650.</li>
<li>Keefe, Bruyette &amp; Woods <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/588f38ae77f9dd00016a51b4/sanjay-sakhrani">analyst Sanjay Sakhrani</a> maintained an Outperform rating, while lifting the price target from $618 to $665.</li>
<li>Raymond James <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e53e894ece4e600011fe266/will-nance">analyst John Davis</a> reiterated an Outperform rating, while raising the price target from $614 to $640.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs: Mastercard reported its fourth-quarter total net revenues at around $7.489 billion. The payments company beat the consensus of $7.389 billion, up 16% year-on-year in constant currency terms. Payment Network outperformed expectations, while Value-added Services and Solutions underperformed, Nance said.
While us volume trends were largely above expectations, international volumes were mixed, the analyst stated. "Shares outperformed, which we would attribute to the stronger than expected underlying revenue guide," he further wrote.
KeyBanc Capital Markets: Mastercard reported adjusted earnings of $3.82 per share, topping Street expectations of $3.70 per share, Markgraff said. Payment Network generated revenues of $4.41 billion. That&#8217;s higher than consensus of $4.28 billion. Value-Added Services and Solutions recorded revenues of $3.08 billion, missing expectations of $3.11 billion.
"Management noted that macro conditions continue to improve, underpinned by healthy consumer spending with strong labor market conditions and moderated inflation, while remaining positive on the prospect of expected global economic expansion in 2025," the analyst wrote. Mastercard's revenues and earnings in 2025 is likely to be impacted by "substantial FX and M&amp;A-related headwinds," he further stated.
RBC Capital Markets: Mastercard's full-year net revenue guidance calls for low double-digit growth on a reported basis, versus Street expectations of 12.1%, Perlin said. "FX is expected to be a ~2% revenue headwind in the year," he added.
Trends remained strong in January, with 13% year-on-year switched volume growth and 18% year-on-year cross-border volume growth, the analyst stated. "The consumer remains healthy and incremental growth opportunities from value-added services and new payment flows stand to act as a shock-absorber to the extent the economic backdrop were to weaken," he further wrote.
Keefe, Bruyette &amp; Woods: Mastercard's US gross dollar volume (GDV) accelerated to 9% year-on-year, from the previous quarter's 7%, "driven by resilient US consumer spending as well as strength in commercial spending," Sakhrani said. Market share gains were not the main growth driver, "strategic initiatives and new partnerships played a crucial role," he added.
Spending trends are "showing signs of improvement driven by consumer strength as well as some benefit from a pickup in crypto transactions," the analyst stated. The company's fundamentals remain "solid," and "a continuation of the accelerated spending trajectory should bode well for upside potential as we move through the year," he further wrote.
Raymond James: Mastercard's quarter to date performance has been "better than feared," Davis said. US switched volume growth accelerated to 10%, given solid holiday spending trends, he added.
"Although total cross-border volume decelerated 200 bp to +18% vs. 4Q, this is related to robust December volumes (+23%) and high-teens growth is consistent with Oct/Nov trends," the analyst wrote. The company's execution was "superb," although there is downside to consensus estimates on FX and deal-related opex, he further stated.
Price Action: Shares of Mastercard had declined by 0.58% to $562.62 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43379151/mastercard-vs-visa-should-you-buy-sell-or-hold-heres-what-technical-analysis-suggest">Mastercard Vs. Visa: Buy, Sell Or Hold? Here&#8217;s What Technical Analysis Suggest</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Trading Ideas

Mastercard Q4 Earnings Beat Estimates, Analysts Raise Forecasts On Continued Strength In US Spending Trends

Keybanc analyst Eric Gonzalez maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Overweight and lowers the price target from $36 to $35.

Keybanc Maintains Overweight on Dine Brands Global, Lowers Price Target to $35

Truist Securities analyst Joel Fishbein reiterates Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Buy and raises the price target from $300 to $350.

TEAM

Truist Securities Reiterates Buy on Atlassian, Raises Price Target to $350

Truist Securities analyst Mark Hughes maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Hold and raises the price target from $275 to $290.

Truist Securities Maintains Hold on Arthur J. Gallagher, Raises Price Target to $290

Cantor Fitzgerald analyst Thomas Blakey maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Neutral and lowers the price target from $58 to $57.

Cantor Fitzgerald Maintains Neutral on Dynatrace, Lowers Price Target to $57

CFLT

Confluent shares are trading higher after Guggenhiem raised its price target on the stock from $32 to $35.

FRME

First Merchants shares are trading higher after Piper Sandler raised its price target on the stock from $52 to $55.

Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) stock originally traded higher on Friday but has since reversed and began trading lower after the company on Thursday reported 2024 fiscal-year <a href="https://www.benzinga.com//node/43354712">fourth-quarter earnings</a>.
 Intel reported sales of $14.30 billion, beating analysts estimate of $13.81 billion, but representing a 7% year-over-year decline. In addition, it reported adjusted earnings per share of 13 cents, beating analysts estimate of 12 cents.
&#8220;Our renewed focus on strengthening and simplifying our product portfolio, combined with continued progress on our process roadmap, is positioning us to better serve the needs of our customers. Dave and I are taking actions to enhance our competitive position and create shareholder value,&#8221; said Michelle Johnston Holthaus, interim co-CEO of Intel and CEO of Intel Products. 
Intel announced guidance for the 2025 fiscal-year first-quarter. It sees revenue between $11.7 billion and $12.7 billion, versus analysts estimate of $12.87 billion. Intel guided Non-GAAP earnings per share of $0, versus analysts estimate of 9 cents.
&#8220;Our&nbsp;Q1&nbsp;outlook&nbsp;reflects seasonal weakness magnified by macro uncertainties, further inventory digestion and competitive dynamics. We will remain highly focused on execution to build on our progress and unlock value,&#8221; said David Zinsner, interim co-CEO and CFO of Intel.
Analyst Changes: Following the earnings report, several analysts issued price target adjustments.
<ul>
<li>Roth MKM analyst Suji Desilva maintained a Neutral rating on Intel and lowered the price target from&nbsp;$25&nbsp;to&nbsp;$20.</li>
<li>Needham analyst Quinn Bolton reiterated a Hold rating on Intel.</li>
<li>Benchmark analyst Cody Acree reiterated a Hold rating on Intel.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/insights/earnings/25/01/43391688/earnings-breakdown-orrstown-finl-servs-q4">Earnings Breakdown: Orrstown Finl Servs Q4</a>
INTC Price Action: At the time of writing, Intel shares are moving 1.04% lower at $19.80, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock.

Movers

INTC

What's Going On With Intel Shares Friday?

AESI

Atlas Energy Solutions shares are trading lower after the company announced a $264.5 million public offering.

Cantor Fitzgerald analyst Sarah James maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and lowers the price target from $400 to $350.

Cantor Fitzgerald Maintains Overweight on Cigna, Lowers Price Target to $350

Adtalem Global Education Inc. Common Stock

ATGE

Adtalem Global Education shares are trading higher after the company raised its FY25 guidance.

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Neutral and raises the price target from $252 to $260.

Piper Sandler Maintains Neutral on ResMed, Raises Price Target to $260

Wells Fargo analyst Michael Turrin maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Overweight and raises the price target from $350 to $375.

Wells Fargo Maintains Overweight on Atlassian, Raises Price Target to $375

Flagstar Financial shares are trading higher after Barclays raised its price target on the stock from $13 to $14.

Phillips 66&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) shares are trading lower on Friday after it&nbsp;reported<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43380949/phillips-66-reports-fourth-quarter-results-and-announces-next-phase-of-strategic-initiatives" rel="noreferrer noopener">&nbsp;fourth-quarter&nbsp;FY24 results</a>.
Midstream segment adjusted pre-tax income rose to $708 million, vs.&nbsp;$672 million&nbsp;in the&nbsp;third quarter&nbsp;of FY24, led by increased NGL margins and volumes.
The Chemicals segment adjusted pre-tax income&nbsp;stood at&nbsp;$72 million&nbsp;versus&nbsp;$342 million&nbsp;in the prior quarter, owing to a decline in margins along with higher turnaround and maintenance costs.
The Refining segment adjusted pre-tax loss improved to $(759)&nbsp;million from $(67) million&nbsp;in the prior quarter due to lower realized margins on reduction in market crack spreads and higher depreciation related to the planned stoppage of operations at the Los Angeles Refinery.
The company reported refining operations with&nbsp;94%&nbsp;crude capacity utilization and&nbsp;88%&nbsp;clean product yield.
The Marketing&nbsp;and Specialties segment adjusted pre-tax income fell significantly to&nbsp;$185 million&nbsp;from&nbsp;$583 million in the prior&nbsp;quarter on seasonally lower margins.
Adjusted EPS of&nbsp;$(0.15) topped&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of&nbsp;$(0.23)</a>.
Phillips 66 reported operating cash flow, excluding working capital impacts, of&nbsp;$901 million in the quarter.
As of Dec. 31, the company reported cash and cash equivalents of $1.7 billion, along with $4.6 billion in committed credit facility capacity.
The company has returned $5.3 billion to shareholders through dividends and share repurchases in 2024
Phillips 66 achieved&nbsp;$1.5 billion in run-rate business transformation savings and synergy capture of $500 million from successful DCP integration.
Strategic Priorities Update: The company plans to return greater than 50% of operating cash flow to shareholders.
Also, Phillips 66 aims to achieve a 2% higher than the industry-average crude utilization and annual adjusted controllable costs of $5.50 per barrel in refining, excluding adjusted turnaround expenses.
The company targets growing Midstream and Chemicals mid-cycle adjusted EBITDA of $1 billion in total by 2027 and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> reducing total debt to $17 billion</a>.
Mark Lashier, chairman and CEO said, "In support of our Midstream wellhead-to-market strategy, we recently announced an agreement to acquire EPIC's NGL business, bolstering our Permian and Gulf Coast footprint,"  
"Upon closing, these assets will be accretive to earnings and highly integrated with our existing infrastructure, providing additional opportunities to enhance returns and shareholder value," he added.
Investors can gain exposure to the stock via&nbsp;IShares U.S. Oil &amp; Gas Exploration &amp; Production ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) and&nbsp;VanEck Oil Refiners ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRAK#NYSE">CRAK</a>).
Price Action: PSX shares are down 2% at $118.33 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43382627" target="_blank" rel="noreferrer noopener">Chevron&nbsp;Q4&nbsp;Earnings: Profits Decline Amid Lower Oil Output, Dividend Hike Offers Silver Lining</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Large Cap

Guidance

CRAK

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

Phillips 66 Stock Under Pressure As Refining Losses Offset Midstream Gains

Mangoceuticals, Inc. (MGRX) has shared an announcement. On August 22, 2024, a company successfully completed a partial sale of its Series B Preferr...

Mangoceuticals Raises Capital and Boosts CEO Perks

Mangoceuticals announces 1-for-15 reverse stock split

"Mangoceuticals (MGRX) learned earlier this morning that Eli Lilly (LLY) has made certain public claims alleging, and has stated that it has filed ...

Mangoceuticals 'refutes' claims by Eli Lilly regarding sale of tirzepatide

The latest update is out from Mangoceuticals, Inc. ( ($MGRX) ). Mangoceuticals, Inc. (MangoRx), a company specializing in men's health products via...

Mangoceuticals Defends Against Eli Lilly Allegations

Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit

Mangoceuticals (MGRX) announced that the Company received a letter on October 30, 2024 from The Nasdaq Stock Market indicating that the Company has...

Mangoceuticals regains full compliance with Nasdaq min bid price requirement

Mangoceuticals, Inc. ( ($MGRX) ) has issued an announcement. Mangoceuticals, Inc. has signed a 12-month consulting agreement with their CFO, Eugene...

Mangoceuticals Signs Consulting Deal with CFO Johnston

Mangoceuticals (MGRX) has launched an investigation into potential stock manipulation related to and following its recent reverse stock split, whic...

Mangoceuticals initiates investigation into potential stock manipulation

Mangoceuticals, Inc. ( ($MGRX) ) has issued an announcement. Mangoceuticals, Inc. has acquired a patent for mushroom-derived nutraceutical composit...

Mangoceuticals Expands with Patent Acquisition in Nutraceuticals

Mangoceuticals, Inc. ( ($MGRX) ) has shared an announcement. Mangoceuticals, Inc. entered into a Debt Conversion Agreement with Mill End Capital Lt...

Mangoceuticals, Inc. Finalizes Debt Conversion and Appointments

MGRX

Screenshot 2024-09-25 at 8.34.28 PM

Health Care

Interview

Men&#39;s Telehealth Company&#39;s Plans To Change Men&#39;s Wellness

Screenshot 2024-09-04 at 5.36.44 PM

Biotech

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Screenshot 2024-07-24 at 5.47.14 PM

Emerging Markets

Markets

This Men&#39;s Telehealth Company Has A Unique Take On Telehealth And Products

Screenshot 2024-07-17 at 5.41.58 PM

Say Goodbye To Inconvenient TRT: Meet The Game-Changing Oral Testosterone Treatment - PRIME By MangoRx

Screenshot 2024-07-09 at 1.59.17 PM

Erectile Function Vs Erectile Dysfunction: How MangoRx&#39;s (NASDAQ: MGRX) Product Sets Itself Apart And Caters To A Large Market (Pun Intended)

Men's Telehealth Company's Plans To Change Men's Wellness

Press Releases

MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment

Shares of Healthcare Company Rise Following Product Availability Announcement

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions

MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN

MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly

MangoRx Announces Formation of Strategy and Alternatives Committee

Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split

Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

UPXI

China Jo-Jo Drugstores, Inc. - Ordinary Shares

China Jo-Jo Drugstores

Guardian Pharmacy Services, Inc. Class A Common Stock

Guardian Pharmacy Service

Walgreens Boots Alliance, Inc. - Common Stock

Comments

Mangoceuticals

Noticias

Últimas noticias sobre Mangoceuticals (NASDAQ:MGRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL